ClinicalTrials.gg
RecruitingNCT04434807EVACUATEUpdated Oct 28, 2025

Ultra-Early, Minimally inVAsive intraCerebral Haemorrhage evacUATion Versus Standard trEatment

An interventional study of Minimally invasive hematoma evacuation in Intra Cerebral Hemorrhage and Stroke, sponsored by University of Melbourne. Recruiting at 13 sites in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-28.

Sponsored by University of Melbourne · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2020; still recruiting 6 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Cerebral Hemorrhage with a site in Australia — 5 open to participants now, 6 under way, 2 of them phase 3. Cerebral Hemorrhage · Australia.

Planned enrollment
13th of 18
240 · median 452
Started
2020
with 1 other
No phase
7 of 20
1 open now
Registered
15th of 20
by date
Lead sponsor
1 of 20
University of Melbourne

Among the 20 studies in Cerebral Hemorrhage with a site in Australia, this one is the 13th largest by planned enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2020, is one of 7 with no phase, and was the 15th registered.

Cerebral Hemorrhage

458 studies on the registry are indexed under Cerebral Hemorrhage; 173 are open to participants now.

Browse Cerebral Hemorrhage studies →

Open to participants now

5 of the 20 studies in Cerebral Hemorrhage with a site in Australia are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 115 Cerebral Hemorrhage studies recruiting now, 61 (53%) set no upper age limit and 9 (8%) stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Cerebral Hemorrhage with a site in Australia, or all of them as a file.
02

Study summary

A randomized controlled trial of ultra-early, minimally invasive, hematoma evacuation versus standard care within 8 hours of intracerebral hemorrhage. Patients presenting to the emergency department with stroke due to supratentorial, spontaneous intracerebral hemorrhage >20mL volume will be assessed to determine their eligibility for randomization into the trial. If the patient gives informed consent they will be randomized 50:50 using central computerized allocation to minimally invasive hematoma evacuation using the Aurora surgiscope and evacuator (Integra Lifesciences) versus standard medical therapy. The trial is prospective, randomized, open-label, blinded endpoint (PROBE) design with seamless phase 2b-3 transition if the intermediate endpoint (successful hematoma evacuation) is met in analysis of the first 52 patients. Adaptive sample size re-estimation (Mehta and Pocock) will be performed when 160 patients have completed 6 month follow-up (minimum sample size 240, maximum sample size 434).

03

Conditions studied

  • Intra Cerebral Hemorrhage
  • Stroke

Keywords

  • neurosurgery
  • minimally invasive
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with an acute supratentorial intracerebral hemorrhage (ICH) ≥20mL in volume
  2. Age ≥18 years
  3. Surgery can commence within 8 hours of symptom onset (the time the patient was last known to be well) or, in patients with wake-up onset, within 8 hours of the time the patient awoke with symptoms. Patients presenting with small ICH (volume \<20mL) with clinical deterioration judged due to ICH hematoma expansion meeting volume criteria may be randomized if surgery can commence within 8 hours of clinical deterioration
  4. Moderate neurological deficit (NIHSS≥6)
  5. Pre-stroke mRS ≤3 (independent function or requiring only minor domestic assistance and able to manage alone for at least 1 week).
  6. CTA or MRA is performed and does not show an underlying vascular lesion

Exclusion criteria

Exclusion Criteria:

  1. Brainstem ICH
  2. ICH secondary to trauma, where brain injury is judged more likely to be due to the broad effects of trauma rather than the focal ICH.
  3. Hereditary or acquired hemorrhagic diathesis or coagulation factor deficiency (in liver disease, >1.4).
  4. count \<75,000
  5. Unreversible heparinization or anticoagulation. If reversing warfarin, INR should be ≤1.4 before procedure commences. Reversal of heparin by protamine, dabigatran by idarucizumab and rivaroxaban, apixaban and enoxaparin by andexanet (where available) is permitted. Unreversed anticoagulation with a last dose within 48 hours is an exclusion.
  6. Recent (\<12 hours) parenteral GPIIb/IIIa antagonist.
  7. Recent (\<1 hour) thrombolysis. If the ICH has occurred between 1 and 12 hours following thrombolysis, cryoprecipitate (1U per 10kg) and tranexamic acid must be administered prior to treatment.
  8. Participation in any study in the last 30 days
  9. Pregnant women (clinically evident)
  10. Co-morbidities or advance care directive preventing general anaesthesia for the procedure.
  11. Known terminal illness such that the patients would not be expected to survive a year.
  12. Planned withdrawal of care or comfort care measures.
  13. Any condition that, in the judgment of the investigator could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    Minimally invasive hematoma evacuation

    Patients randomized to minimally invasive hematoma evacuation will have neurosurgery followed by standard medical therapy in a stroke care unit or intensive care unit, as appropriate to the patients clinical condition.

    Procedure: Minimally invasive hematoma evacuation

  • No intervention
    Standard care (medical therapy)

    Patients randomized to medical management will receive the standard medical therapies for the treatment of intracerebral hemorrhage in a stroke care unit or intensive care unit, as appropriate to the patients clinical condition, with no planned surgical intervention.

Interventions

  • ProcedureMinimally invasive hematoma evacuation

    Neurosurgery performed via burr hole or minicraniotomy and using the Aurora surgiscope and evacuator (Integra Lifesciences)

06

What researchers measure

Primary outcomes

  1. Dichotomized Modified Rankin Scale Score 0-3 vs. 4-6 at 6 months post-onset (Adjusted)

    Modified Rankin Scale (mRS) 0-3 at 6 months, adjusted for age, baseline GCS, immediate pre-treatment ICH volume and immediate pre-treatment IVH volume.

    Time frame: 6 months post-stroke

Secondary outcomes

  1. Dichotomized Modified Rankin Scale Score 0-2 or no change from baseline vs. 3-6 at 6 months post-onset (adjusted)

    Modified Rankin Scale (mRS) 0-2 or no change from baseline at 6 months, adjusted for age, baseline GCS, immediate pre-treatment ICH volume and immediate pre-treatment IVH volume

    Time frame: 6 months post-stroke

  2. Ordinal analysis of Modified Rankin Scale Score at 6 months post-onset (adjusted)

    Ordinal analysis of Modified Rankin Scale Score (merging mRS 5-6) at 6 months, adjusted for age, baseline GCS, immediate pre-treatment ICH volume and immediate pre-treatment IVH volume

    Time frame: 6 months post-stroke

  3. Utility-weighted analysis of Modified Rankin Scale Score at 6 months post-onset (adjusted)

    Utility-weighted analysis of Modified Rankin Scale Score at 6 months, adjusted for age, baseline GCS, immediate pre-treatment ICH volume and immediate pre-treatment IVH volume

    Time frame: 6 months post-stroke

  4. Reduction in hematoma volume at 24 hours >70% or <15mL residual volume (adjusted)

    Reduction in hematoma volume at 24 hours \>70% or \<15mL residual volume, adjusted for immediate pre-treatment ICH volume

    Time frame: 24 hours post-randomization

  5. Proportion of patients with early neurological improvement at 7 days (adjusted)

    Proportion of patients with ≥8 point reduction in National Institutes of Health Stroke Scale (NIHSS) score or reaching 0-1 at 7 days (or at discharge if earlier) adjusted for baseline NIHSS and age

    Time frame: 7 days post-stroke

Other outcomes

  1. Safety: Death due to any cause at 6 months (adjusted)

    Death due to any cause at 6 months, adjusted for age, baseline GCS, immediate pre-treatment ICH volume and immediate pre-treatment IVH volume.

    Time frame: 6 months post-stroke

  2. Safety: Hematoma growth or reaccumulation at 24 hours

    Hematoma growth or reaccumulation defined as \>33% or \>6mL increased volume between baseline and 24 hour scans (or in the intervention arm a hematoma volume on the follow-up scan exceeding the immediate pre-treatment volume), adjusted for the pre-treatment ICH volume.

    Time frame: 24 hours post-randomization

  3. Intermediate outcome measure (primary outcome measure for Phase 2b component): Reduction in hematoma volume at 24 hours >70% or <15mL residual volume (adjusted)

    Intermediate outcome measure (primary outcome measure for the Phase 2b component to be analysed for the first 52 patients): Reduction in hematoma volume at 24 hours \>70% or \<15mL residual volume, adjusted for immediate pre-treatment ICH volume

    Time frame: 24 hours post-randomization

  4. Patient Reported Outcomes Measurement Information System (PROMIS10)

    Time frame: 6 and 12 months post-stroke

  5. Modified Rankin Scale (mRS) 0-2, 0-3, ordinal and utility-weighted analysis at 12 months

    Time frame: 12 months post-stroke

  6. Assessment of Quality of Life (EQ5D) at 12 months

    Assessment of Quality of Life (EQ5D) at 12 months (mapped to mRS at baseline)

    Time frame: 12 months post-stroke

  7. Length of stay in intensive care unit, acute hospital, acute hospital and rehabilitation

    Time frame: 6 months post-stroke

  8. Home time - time spent at home in the first 6 months

    Time frame: 6 months post-stroke

07

Study locations

7 of 13 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual patient data will be uploaded to the Virtual Stroke Trials Archive (http://www.virtualtrialsarchives.org/vista/) 2 years after the publication of the primary manuscript. Qualified investigators can access data after submission of a project proposal that has been approved by the VISTA-ICH steering committee.

Time frame: 2 years after the publication of the primary manuscript

Access criteria: Qualified investigators can access data after submission of a project proposal that has been approved by the VISTA-ICH steering committee.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2020 (actual). Primary completion is estimated for Dec 2027, 85 months after the start.

Of 77 non-industry interventional studies with no phase under Cerebral Hemorrhage, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 75. This study's planned 85 months is above that.

Counting every sponsor, half of 85 studies reached it within 38 months; a quarter within 19 and three quarters within 72.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2020
First posted
Jun 17, 2020
StartActual
Nov 15, 2020
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2028
Last update
Oct 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04434807
Lead sponsor
University of Melbourne
Responsible party
Bruce Campbell (Professorial Fellow, Department of Medicine, Royal Melbourne Hospital, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne) — Principal investigator
First posted
Jun 17, 2020
Start date
Nov 15, 2020
Primary completion
Dec 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Oct 28, 2025

Study contacts

Melbourne Brain Centre at the Royal Melbourne Hospital
Contact
info@thembc.org.au
+61 3 9342 4424
Timothy Kleinig
principal investigator · Royal Adelaide Hospital/University of Adelaide
Amal Abou-Hamden
principal investigator · Royal Adelaide Hospital/University of Adelaide
John Laidlaw
principal investigator · Royal Melbourne Hospital/University of Melbourne
J Mocco
principal investigator · Icahn School of Medicine, Mt Sinai Hospital, New York
Christopher Kellner
principal investigator · Icahn School of Medicine, Mt Sinai Hospital, New York
Stephen Davis
principal investigator · Royal Melbourne Hospital/University of Melbourne
Bruce Campbell
principal investigator · Royal Melbourne Hospital/University of Melbourne

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion